Share on StockTwits

GenMark Diagnostics (NASDAQ:GNMK) saw a large decrease in short interest in the month of August. As of August 15th, there was short interest totalling 4,526,618 shares, a decrease of 24.9% from the July 31st total of 6,025,377 shares, American Banking and Market News reports. Based on an average daily volume of 139,106 shares, the days-to-cover ratio is presently 32.5 days. Currently, 11.7% of the company’s shares are sold short.

Separately, analysts at Raymond James reiterated an “outperform” rating on shares of GenMark Diagnostics in a research note on Tuesday, August 12th. They now have a $13.00 price target on the stock, up previously from $11.00. Five equities research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus target price of $15.33.

GenMark Diagnostics (NASDAQ:GNMK) opened at 10.77 on Wednesday. GenMark Diagnostics has a one year low of $8.48 and a one year high of $14.18. The stock’s 50-day moving average is $10.93 and its 200-day moving average is $10.97. The company’s market cap is $449.4 million.

GenMark Diagnostics (NASDAQ:GNMK) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.27) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.29) by $0.02. The company had revenue of $6.55 million for the quarter, compared to the consensus estimate of $4.79 million. During the same quarter in the prior year, the company posted ($0.25) earnings per share. The company’s quarterly revenue was up 26.9% on a year-over-year basis. Analysts expect that GenMark Diagnostics will post $-1.13 EPS for the current fiscal year.

GenMark Diagnostics, Inc (NASDAQ:GNMK) is a molecular diagnostics company focused on developing and commercializing its eSensor detection technology.

Receive News & Ratings for GenMark Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.